HIGHLIGHTS
- who: Akt and colleagues from the University of Milan, Italy have published the paper: The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients, in the Journal: (JOURNAL)
- how: This study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the Ethics Committee of The demographic and clinical features were obtained at baseline and clinical symptoms laboratory data medications and SLE Disease Activity Index 2000 (SLEDAI-2K) (Gladman et_al 2002) were ascertained at each follow-up point. The B . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.